Exploring systems neuroscience, neural circuit dysfunction, network pharmacology, and the emerging science of treating complex neurological conditions
Biotech International Institute (BII)
The Next Frontiers in Neuroscience — Friday, October 23, 2026
Introduction: Is One Molecular Target Enough to Understand the Brain?
For decades, much of modern drug discovery has been organized around a powerful scientific idea:
Identify a biological target, develop a molecule that interacts with it, and investigate whether changing that target produces a meaningful therapeutic effect.
This approach has contributed to important advances in medicine.
Receptors, enzymes, ion channels, and transporters remain central to pharmacology.
But the human brain presents a particularly difficult challenge.
The brain does not operate one receptor at a time.
It operates through interconnected systems.
Neurons communicate across circuits.
Immune cells influence the neural environment.
Neurotransmitter systems interact.
Stress responses influence memory and behavior.
Neuroplasticity changes how circuits respond to experience.
And biological signals continuously influence one another.
A molecule may interact with one receptor, but the consequences of that interaction can extend across an entire signaling network.
This raises one of the most intriguing questions in contemporary neuroscience:
Could understanding networks, rather than isolated molecular targets alone, lead to better approaches for investigating neurological and psychiatric disorders?
At Biotech International Institute, this question is relevant to the scientific foundations of our three research-stage small-molecule platforms: Neurophorol™, Mycophorol™, and NeuroReset™.
But the answer requires understanding an important distinction.
Studying networks does not automatically mean a molecule should interact with many targets.
It means researchers must understand the larger biological systems in which molecular targets operate.
---
1. The Brain Is a Network of Networks
The brain contains billions of neurons connected through complex patterns of communication.
These connections form circuits that support memory, attention, movement, reward processing, emotional regulation, and many other functions.
But neuronal connections represent only one level of organization.
The brain also contains interacting molecular and cellular networks.
These include:
- Neurotransmitter signaling systems
- Immune and inflammatory pathways
- Neurotrophic signaling networks
- Metabolic and mitochondrial processes
- Glial communication
- Vascular and blood-brain barrier systems
- Hormonal and stress-response pathways
- Gene-regulatory networks
These systems influence one another.
For example, inflammatory signaling can affect neuronal function.
Stress-related changes can influence reward processing.
Neurotrophic signaling can influence synaptic adaptation.
Metabolic conditions can alter neural activity.
This interconnected organization creates both resilience and vulnerability.
A network may compensate when one component changes.
But disturbances in one system may also influence several others.
Understanding these relationships is fundamental to systems neuroscience.
2. Why the Single-Target Model Has Limitations
Traditional target-based drug discovery begins by identifying a molecule or protein associated with a disease-related process.
Researchers then investigate compounds that interact with that target.
This remains a valuable strategy.
Selective molecular interventions can help establish mechanisms and limit unwanted interactions.
However, complex neurological conditions may involve several biological processes operating simultaneously.
Alzheimer's disease, for example, involves interacting mechanisms related to protein pathology, synaptic dysfunction, immune signaling, vascular biology, and other processes.
Substance-use disorders involve reward circuitry, associative learning, stress responses, motivation, and environmental influences.
Some psychiatric disorders involve altered activity across interconnected neural circuits rather than dysfunction in one isolated brain region.
A compound may successfully engage its intended molecular target without producing a clinically meaningful result.
That can happen for several reasons.
The selected target may not be a major driver of the condition.
Biological pathways may compensate.
The disease may involve mechanisms not addressed by the intervention.
Or target engagement may fail to translate into meaningful functional improvement.
A precisely targeted molecule can be pharmacologically active without being therapeutically effective.
That distinction explains why systems-level research is increasingly important.
3. Network Neuroscience: Understanding the Brain's Connections
Network neuroscience examines how different parts of the nervous system interact.
Researchers use tools such as functional magnetic resonance imaging, electrophysiology, computational modeling, and other methods to investigate patterns of communication.
Instead of asking only whether one region is active, investigators can examine how regions coordinate their activity.
A 2024 research highlight in Nature Reviews Neuroscience discussed work investigating relationships between brain functional networks and psychiatric disorders.
Such research raises questions about whether particular patterns of network dysfunction contribute to clinical conditions.
However, interpreting network differences requires caution.
A change in functional connectivity does not automatically establish a cause of disease.
It may reflect a consequence, compensation, or an association involving another underlying process.
This is a recurring challenge in neuroscience.
A network pattern can be measurable without revealing exactly what causes it.
Understanding causality requires additional experimental evidence.
4. Neural Circuit Dysfunction and Emotional Regulation
One example of network-level research involves anxiety and related emotional processes.
Neural systems involved in threat detection, reward evaluation, emotional learning, and cognitive control interact continuously.
Researchers have investigated how altered communication across these systems may contribute to pathological anxiety.
A 2025 review in Nature Reviews Neuroscience examined the neural circuit basis of anxiety disorders.
The authors emphasized that clinically relevant symptoms can involve multiple interacting circuits rather than one isolated neural structure.
This creates an important research opportunity.
Instead of studying only the presence or absence of a neurotransmitter, researchers can investigate how molecular signaling changes circuit function.
But circuit-level findings still require careful translation.
A network abnormality identified in imaging does not automatically identify the best drug target.
And normalizing a laboratory measurement does not necessarily establish meaningful clinical improvement.
5. From Network Neuroscience to Network Pharmacology
Network pharmacology takes a related concept into drug discovery.
It examines how compounds, molecular targets, biological pathways, and disease-associated processes are connected.
A drug may affect one primary target.
That target may influence several downstream pathways.
Alternatively, a compound may interact directly with multiple molecular targets.
Researchers can use network models to investigate these relationships.
A 2025 review in the Annual Review of Biomedical Data Science discussed how network-based methods can integrate molecular interactions and multiple types of biological data to improve drug-target identification.
The review also acknowledged important limitations in translating network predictions into clinical results.
This distinction matters.
A computational model may suggest that a target occupies an important position within a biological network.
But that does not prove changing the target will produce a useful therapeutic effect.
The prediction must be tested experimentally.
6. Polypharmacology: When One Molecule Interacts With Multiple Targets
Polypharmacology refers to pharmacological activity involving multiple molecular targets.
Historically, interactions with targets other than the intended one were often discussed primarily as off-target effects.
Many such interactions are undesirable.
They can contribute to toxicity, drug interactions, and unexpected biological responses.
But researchers also recognize that some medicines exert useful effects through more than one target.
This has encouraged investigation into multi-target-directed ligands.
These are molecules designed or studied for activity across multiple biological targets.
In principle, a multi-target approach could influence several related disease mechanisms.
However, complexity increases.
Researchers must investigate whether the compound has the intended activity at each target, whether relevant exposures are achievable, and whether the combined pharmacology introduces unacceptable risks.
More targets do not automatically mean a better medicine.
Sometimes selective targeting is preferable.
Sometimes a multi-target approach may be worth investigating.
The best strategy depends on the biological problem and the supporting evidence.
7. The Importance of Biological Compensation
One reason network thinking matters is that biological systems can compensate.
When one signaling pathway changes, another may respond.
When a receptor is inhibited, cells may adjust downstream signaling or receptor expression.
When a neural circuit loses some activity, other networks may alter their behavior.
This adaptability is often essential for normal physiology.
But it can complicate treatment development.
A compound may produce a strong initial molecular response, while longer-term effects become smaller or change direction.
Researchers therefore need to investigate not only immediate receptor engagement but also downstream and longer-term biological responses.
This is particularly relevant when studying neuroplasticity.
The nervous system is designed to adapt.
That adaptability can influence how pharmacological effects evolve over time.
8. Neuroimmune Networks: More Than Inflammation
Monday's article explored the role of microglia in neurological function.
This provides an example of network biology.
Microglia interact with neurons, astrocytes, immune signaling molecules, and other components of the neural environment.
Inflammatory responses may influence synaptic activity.
Neuronal signaling may influence microglial behavior.
Changes in metabolism and cellular stress may affect both systems.
This means neuroimmune research cannot always be reduced to measuring whether one inflammatory biomarker increases or decreases.
Researchers must investigate context.
Which cells are responding?
Which signaling pathway is involved?
Is the response protective, harmful, compensatory, or unrelated to the proposed mechanism?
How does it influence neuronal function?
Could receptor-specific pharmacology alter a particular response without disrupting beneficial immune activity?
These questions are central to understanding the intersection of neural and immune networks.
9. Neurophorol™: Receptor Precision Within a Larger Network
At Biotech International Institute, Neurophorol™ represents our research-stage CB2-oriented cannabinoid small-molecule platform.
Its proposed research focus includes cannabinoid receptor pharmacology, receptor selectivity, and neuroimmune signaling.
Network neuroscience provides a useful perspective for this work.
CB2-related signaling may be studied within broader immune and neural processes.
But the first task remains establishing the pharmacology of the investigational compound.
Does it interact with CB2?
How does its activity compare with CB1?
Does it exhibit functional signaling?
Are relevant off-target interactions present?
Can observed cellular effects be attributed to the proposed receptor mechanism?
Only after these questions are addressed can researchers begin evaluating broader pathway relationships.
This illustrates an important principle.
Network awareness does not replace receptor precision. It makes receptor precision more meaningful.
BII has not demonstrated that Neurophorol™ modifies neurological networks, treats neuroinflammation, or produces therapeutic benefit.
These remain questions for future investigation.
10. Neurotrophic Networks: How Neurons Adapt
Tuesday's article explored the relationship between psychedelic-associated signaling and neuroplasticity.
This provides another example of network-level biology.
Neurotrophic signaling involves interconnected molecular pathways influencing neuronal function and adaptation.
BDNF and TrkB are important components of this biology.
Their downstream signaling can interact with other systems affecting synaptic structure, neuronal activity, and cellular responses.
However, neural adaptation is not controlled by one neurotrophic protein.
Multiple molecular and cellular processes contribute.
The outcome may depend on the brain region, cell type, activity pattern, exposure, and biological conditions.
This means observing a change in one neurotrophic marker does not establish that a broader neuronal network has improved.
Researchers must investigate what the molecular response means functionally.
11. Mycophorol™: Studying Neurotrophic Pathways in Context
Mycophorol™ represents BII's psilocybin/fungi-inspired small-molecule research platform.
Its proposed scientific direction includes neurotrophic-pathway questions, neuronal adaptation, and neural-resilience biology.
A network-informed approach may help researchers frame future studies.
For example, investigators could examine whether a defined compound interacts with a specific receptor or signaling pathway.
They could then ask whether downstream changes involve relevant neurotrophic markers.
Additional experiments would be needed to determine whether those changes influence cellular or functional outcomes.
The important question is not simply whether BDNF-related signaling changes.
It is whether the observed response is reproducible, mechanism-linked, and biologically meaningful.
BII has not established that Mycophorol™ improves network connectivity, cognition, memory, or neurological resilience.
The platform remains research-stage and requires direct experimental validation.
12. Recovery Biology May Be a Network-Level Challenge
Wednesday's article examined whether recovery from substance dependency involves erasing established neural associations or developing new adaptive responses.
That question connects directly to network neuroscience.
Substance-use-related adaptation involves multiple interacting systems.
Reward processing influences behavior.
Stress can affect motivation and cue-related responses.
Memory systems contribute to learned associations.
Prefrontal circuits participate in behavioral regulation.
Neuroimmune and metabolic conditions may influence broader neurological function.
Recovery also involves learning, environment, and personal circumstances.
A single molecular target may influence one component of this system.
But understanding recovery requires a broader view.
The biology of recovery cannot be fully explained by one receptor or one neural circuit.
This does not mean multi-target pharmacology will necessarily produce better outcomes.
It means scientific models must recognize the complexity of the condition being investigated.
13. NeuroReset™: A Multi-Pathway Research Question
NeuroReset™ represents BII's research-stage psilocybin/cannabinoid small-molecule direction focused on post-dependency recovery biology.
Its scientific interests include reward circuitry, stress response, neuroplasticity, neuroimmune signaling, and neural adaptation.
A systems-level perspective is particularly relevant.
Researchers must first define the actual investigational candidate or candidates.
They must establish chemical identity and pharmacological activity.
Then they can investigate which biological pathways are relevant and whether specific experimental models can meaningfully measure those relationships.
If more than one compound or target is involved, interactions become an important concern.
Potential changes in exposure, metabolism, receptor signaling, and safety must be investigated.
A multi-pathway hypothesis is not evidence of a multi-pathway therapeutic benefit.
BII has not demonstrated that NeuroReset™ resets neural networks, reverses dependency-related adaptations, prevents relapse, or treats addiction.
The scientific objective is to establish testable hypotheses rather than assume outcomes.
14. The Blood-Brain Barrier Adds Another Network Dimension
Thursday's article examined the blood-brain barrier.
This protective interface demonstrates why molecular pharmacology cannot be separated from physiology.
A compound may show receptor activity in a laboratory system.
But its ability to influence a brain-associated mechanism depends partly on whether the relevant target is accessible.
The blood-brain barrier includes transporters, endothelial cells, glial interactions, and other components of the neurovascular unit.
These systems regulate molecular exchange.
For direct central nervous system targets, exposure may be a limiting factor.
For mechanisms involving peripheral immune pathways, direct brain entry may not always be required.
A network-informed drug-development strategy must therefore integrate molecular pharmacology with distribution and target location.
Understanding where the target operates is as important as understanding what the molecule does.
15. Artificial Intelligence and the Challenge of Biological Networks
Modern neuroscience produces enormous amounts of biological data.
Genomic information.
Protein interactions.
Receptor measurements.
Single-cell profiles.
Neuroimaging results.
Electrophysiological recordings.
Behavioral observations.
Artificial intelligence and computational systems may help researchers identify relationships within these datasets.
They can assist in generating hypotheses, prioritizing targets, and identifying patterns.
A 2026 review in Nature Reviews Drug Discovery examined the growing use of AI in drug-target identification and assessment.
But AI does not remove the need for experimental validation.
A network prediction may identify an interesting association.
It does not automatically establish biological causality.
For BII, AI-assisted technical analysis can help organize research priorities, but proposed mechanisms must still be tested with appropriate laboratory methods.
Computational insight should guide experimentation, not replace it.
16. Why More Complex Models Are Not Always Better
Network science offers powerful tools.
But complexity itself is not evidence of scientific quality.
A model containing thousands of molecular interactions may look sophisticated while depending on incomplete or uncertain assumptions.
Some network relationships are well supported experimentally.
Others may be inferred from statistical associations or computational predictions.
A large model may also be difficult to interpret or validate.
Researchers must therefore ask:
Which connections are supported by reliable evidence?
Which are hypothetical?
Can the model generate predictions that can be tested?
Does it improve decisions compared with simpler approaches?
Does it account for biological differences between experimental models and humans?
The best model is not necessarily the one containing the most components.
It is the one that helps answer a meaningful scientific question reliably.
17. The Next Frontier: From Molecular Targets to Functional Outcomes
One of the greatest challenges in neurological drug discovery is connecting molecular activity to outcomes that matter.
A compound may bind to a receptor.
A signaling pathway may change.
A biomarker may respond.
A neural circuit may show altered activity.
But each result represents a different level of evidence.
A useful research strategy must connect these levels.
Molecular activity must be interpreted in relation to exposure.
Exposure must be connected to target engagement.
Target engagement must be connected to appropriate biological responses.
Functional changes must be evaluated in relevant experimental systems.
And potential clinical benefits must ultimately be demonstrated through appropriately designed human studies.
The future of brain medicine may increasingly depend on understanding these connections rather than treating each measurement as an isolated result.
18. What Scientists Still Need to Discover
Despite advances in systems neuroscience, many major questions remain.
Which network changes are causes of neurological dysfunction, and which are consequences?
Can researchers reliably identify the most important points within complex biological networks?
When is a selective drug preferable to a multi-target approach?
How do compensatory pathways influence long-term treatment responses?
Can molecular changes be linked reliably to neural circuit function?
How do immune signaling, neuroplasticity, metabolism, and vascular systems interact during neurological disease?
Can computational models improve the selection of drug targets and experimental studies?
And can network-level understanding eventually improve treatment outcomes without increasing safety risks?
These are important questions because the brain's complexity presents both an obstacle and an opportunity.
Closing Thought: The Future May Require Thinking Beyond One Receptor
Modern neuroscience is teaching us that neurological function emerges from interacting biological systems.
Neurons do not operate independently.
Receptors do not exist outside signaling networks.
Immune pathways do not function separately from the nervous system.
Neuroplasticity cannot be reduced to one protein.
And recovery from complex neurological conditions cannot be understood through one molecular mechanism alone.
This does not make targeted pharmacology obsolete.
It makes the relationship between molecular precision and systems-level understanding more important.
For Biotech International Institute, this perspective informs the research questions behind Neurophorol™, Mycophorol™, and NeuroReset™.
Our objective is not to assume that complex biology can be solved by combining more targets.
It is to investigate carefully defined molecular mechanisms within the larger systems that give those mechanisms meaning.
The next frontier of brain medicine may not be choosing between molecular targets and biological networks.
It may be learning how to connect them.
That is where some of the most important questions in future neurological research may be found.
Research-stage. Built for validation.
Mechanism first. Validation always.
Biotech International Institute
Science. People. Communities. A Healthier Tomorrow.
---
Scientific References
1. Koutsandreas, T., et al. (2025).
Network-Based Approaches for Drug Target Identification.
Annual Review of Biomedical Data Science, 8, 423–446.
https://doi.org/10.1146/annurev-biodatasci-101424-120950
2. Ryszkiewicz, P., Malinowska, B., & Schlicker, E. (2025).
Polypharmacology: New Drugs in 2023–2024.
Pharmacological Reports, 77, 543–560.
https://doi.org/10.1007/s43440-025-00715-8
3. Akiki, T. J., et al. (2025).
Neural Circuit Basis of Pathological Anxiety.
Nature Reviews Neuroscience, 26, 5–22.
https://doi.org/10.1038/s41583-024-00880-4
4. Pun, F. W., et al. (2026).
Target Identification and Assessment in the Era of AI.
Nature Reviews Drug Discovery, 25, 534–552.
https://doi.org/10.1038/s41573-026-01412-8
5. Halip, L., et al. (2026).
The Evolving Landscape of Drug Targets.
Nature Reviews Drug Discovery. Published September 21, 2026.
https://doi.org/10.1038/s41573-026-01530-3
Research disclosure: Neurophorol™, Mycophorol™, and NeuroReset™ are research-stage BII platform directions. Published network neuroscience and pharmacology findings are not evidence that BII's investigational compounds modify neural networks, demonstrate clinical efficacy, or have established safety. Proposed mechanisms require direct experimental validation.
